TipRanks
Advertisement
Advertisement

CH:DUL Stock Latest News

Alnylam price target lowered to $369 from $375 at JPMorgan
The FlyAlnylam price target lowered to $369 from $375 at JPMorgan
20h ago
ALNY
Alnylam announces launch of AMVUTTRA ‘Play by Play’ initiative
PremiumThe Fly
Alnylam announces launch of AMVUTTRA ‘Play by Play’ initiative
2d ago
ALNY
Analyst Maintains Buy Rating on Alnylam, Reiterates $357 Price Target on Long-Term Zilebesiran Opportunity
PremiumRatings
Analyst Maintains Buy Rating on Alnylam, Reiterates $357 Price Target on Long-Term Zilebesiran Opportunity
14d ago
ALNY
Hold Rating Reaffirmed as TTR Outlook Moderates; $300 Price Target Maintained
PremiumRatings
Hold Rating Reaffirmed as TTR Outlook Moderates; $300 Price Target Maintained
19d ago
ALNY
Alnylam price target raised to $260 from $230 at Jefferies
PremiumThe Fly
Alnylam price target raised to $260 from $230 at Jefferies
23d ago
ALNY
Alnylam’s Emerging TTR Leadership Reinforces Buy Rating with Unchanged $455 Price Target
PremiumRatingsAlnylam’s Emerging TTR Leadership Reinforces Buy Rating with Unchanged $455 Price Target
29d ago
ALNY
Whitney Ijem Reiterates Buy on Alnylam, Keeps Price Target Unchanged at $429 Following CARDIO‑TTRansform Data
Premium
Ratings
Whitney Ijem Reiterates Buy on Alnylam, Keeps Price Target Unchanged at $429 Following CARDIO‑TTRansform Data
1M ago
ALNY
Alnylam Upgraded to Buy on Strong ATTR Cardiomyopathy Positioning and Amvuttra Mega-Blockbuster Potential
Premium
Ratings
Alnylam Upgraded to Buy on Strong ATTR Cardiomyopathy Positioning and Amvuttra Mega-Blockbuster Potential
1M ago
ALNY
Alnylam Maintained at Buy as Analyst Reaffirms $346 Price Target on TTR Franchise Strength and Amvuttra Growth Visibility
PremiumRatings
Alnylam Maintained at Buy as Analyst Reaffirms $346 Price Target on TTR Franchise Strength and Amvuttra Growth Visibility
1M ago
ALNY
Alnylam announces new data at ESC Congress on AMVUTTRA
PremiumThe Fly
Alnylam announces new data at ESC Congress on AMVUTTRA
1M ago
ALNY
Ionis, AstraZeneca ATTR-CM trial did not meet primary endpoint
PremiumThe Fly
Ionis, AstraZeneca ATTR-CM trial did not meet primary endpoint
1M ago
AZN
ALNY
Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data
PremiumThe Fly
Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data
1M ago
AZN
ALNY
Trump Trade: U.S. considering new semiconductor tariffs
PremiumThe FlyTrump Trade: U.S. considering new semiconductor tariffs
1M ago
MU
AMD
White House to announce drug pricing deals with biotechs, Bloomberg reports
Premium
The Fly
White House to announce drug pricing deals with biotechs, Bloomberg reports
1M ago
ALKS
ALNY
Alnylam to present new clinical data on ATTR, hypertension at ESC Congress
Premium
The Fly
Alnylam to present new clinical data on ATTR, hypertension at ESC Congress
1M ago
ALNY
BMO Capital starts Alnylam at Outperform, sees attractive valuation
PremiumThe Fly
BMO Capital starts Alnylam at Outperform, sees attractive valuation
1M ago
ALNY
Alnylam initiated with an Outperform at BMO Capital
PremiumThe Fly
Alnylam initiated with an Outperform at BMO Capital
1M ago
ALNY
Alnylam award from Veterans Affairs posted to SAM.gov site
PremiumThe Fly
Alnylam award from Veterans Affairs posted to SAM.gov site
1M ago
ALNY
Alnylam price target lowered to $256 from $316 at Wells Fargo
PremiumThe Fly
Alnylam price target lowered to $256 from $316 at Wells Fargo
2M ago
ALNY
Alnylam price target lowered to $325 from $400 at Evercore ISI
PremiumThe FlyAlnylam price target lowered to $325 from $400 at Evercore ISI
2M ago
ALNY
Alnylam price target lowered to $455 from $485 at H.C. Wainwright
Premium
The Fly
Alnylam price target lowered to $455 from $485 at H.C. Wainwright
2M ago
ALNY
Alnylam price target lowered to $315 from $410 at Truist
Premium
The Fly
Alnylam price target lowered to $315 from $410 at Truist
2M ago
ALNY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >